Drug Discovery World

MARCH 2, 2023

With our pre|CISION and Affimer platforms we have an unparalleled opportunity to develop really meaningful new cancer therapies, by developing targeted therapies, multi-specific immunotherapies, difficult to drug targets, and next-generation cell therapies.”

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

JANUARY 18, 2024

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

AUGUST 2, 2024

GLP-1 receptor agonist slows Alzheimer’s cognitive decline In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalisation after 12 weeks of treatment.

Clinical Trials 130

Clinical Trials Drugs Treatment Disease 130

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Discovery World

DECEMBER 7, 2023

New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. The Guiding Principles underpin a new £5 ($6.2)

Bioinformatics 130

Bioinformatics Drugs Clinical Trials Trials 130

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Discovery World

MAY 6, 2024

A more established Amsterdam-based enterprise is gene therapy company uniQure, developer of etranacogene dezaparvovec, the first gene therapy for haemophilia B, which was approved for use in the US in November 2022 and in the EU in February 2023. The rights for etranacogene dezaparvovec were subsequently sold to CSL Pharmaceuticals.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). trillion per year by 2030.

Disease 52

Disease Therapies FDA Trials 52

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

OCTOBER 9, 2021

Alzheimer’s is the most common form of madness, which presently affects farther than 55 million people worldwide, and is projected to reach 78 million by 2030. trillion per space by 2030. Much 10 million people widely are diagnosed with Notice each space.

Disease 52

Disease FDA Therapies Testimonials 52

Drug Discovery World

JULY 31, 2023

DDW’s Reece Armstrong speaks to Hendrik Streefkerk , Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases. million people every year. T his is the market CellProthera wants to enter.

Clinical Trials 130

Clinical Trials Hospitals Therapies Trials 130

Drug Discovery World

AUGUST 14, 2023

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. billion in 2020 to $15.5 billion 1.

Marketing 130

Marketing DNA Therapies FDA 130

The Pharma Data

MARCH 23, 2023

The new state-of-the-art facility will be the largest of its kind in the country and is expected to be operational by around 2030. Takeda has delivered plasma therapies to meet the needs of patients in Japan for more than 70 years. This represents Takeda’s largest ever investment in manufacturing capacity expansion in Japan.

Therapies 40

Therapies Treatment Vaccine Production 40

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease). Join the club.

Small Molecule 140

Small Molecule Trials Therapies Disease 140

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. billion by 2030. Organoids for cell therapy and drug discovery. Mice are often expensive and time-consuming to maintain and breed.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease 52

Disease Science Production Therapies 52

Drug Discovery World

APRIL 25, 2023

Alba Health which is on a mission to reduce chronic disease risks from childhood, leveraging data science and the latest microbiome science. Amplify Therapeutics boasts disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease. billion by 2030.

Science 130

Science Small Molecule Disease Government 130

Drug Discovery World

OCTOBER 6, 2022

until 2030. This growth is due to factors including a rise in speciality medicines, an increase in lifestyle-driven diseases and a growing population 1. The European drug discovery sector is buoyant. Valued at $14.8 billion in 2020, the sector is expected to grow by 8.3% Volume 23 – Issue 4, Fall 2022. References: .

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Therapies 40

Therapies Trials Treatment Disease 40

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

Vial

MAY 20, 2024

billion by 2030 at a compound annual growth rate (CAGR) of 7.5% The clinical phase of drug research is especially important because it tests the findings from preclinical studies in real-life conditions within the target disease population with human volunteers. between 2024 and 2030. What is a Pre-Clinical CRO?

Clinical Research 52

Clinical Research Research Clinical Trials Laboratories 52

The Pharma Data

JULY 15, 2021

Trial will include participants at risk for cognitive and functional decline related to Alzheimer’s disease. TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Clinical Trials Therapies Disease 52

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

SEPTEMBER 28, 2020

Cardiovascular disease (CVD) is a general term for conditions affecting the heart or blood vessels. CVD has many causes: from smoking, diabetes, high blood pressure and obesity, to air pollution, genetic risk factors and less common conditions such as Chagas disease. Developing next-generation therapies.

Disease 52

Disease Therapies Treatment Government 52

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

Drug Discovery World

DECEMBER 12, 2022

Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian 1 that the NHS in the UK believes that by 2030 there will be no new cases of HIV in England. Everyone enjoys a good news story and the drug discovery and development sector is no exception.

Drugs 130

Drugs Engineering Clinical Trials Science 130

The Pharma Data

MARCH 2, 2021

The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. Obesity is a complex chronic disease that requires long-term management.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

JULY 29, 2021

In the second, Lilly shared data showing that treatment with donanemab drives a rapid reduction of a biomarker reflecting Alzheimer’s disease pathology, plasma P-tau217, which was detected within 12 weeks. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data.

Disease 52

Disease Pharmacokinetics Treatment FDA 52

The Pharma Data

NOVEMBER 1, 2020

MS is an autoimmune, inflammatory disease of the central nervous system. billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high unmet medical needs in China and worldwide.

Clinical Trials 52

Clinical Trials FDA Trials Treatment 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies. Strong pipeline with robust late-stage development program and broad potential across indications.

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

SEPTEMBER 30, 2021

Boehringer Ingelheim again joins efforts to fight rabies under this year’s theme for World Rabies Day by GARC: “Rabies: Facts, not Fear” Boehringer Ingelheim strives to raise awareness of the disease and its preventio. A disease like rabies, from which we will best protect humans by immunizing animals, is exemplary to spotlight that.

Vaccine 52

Vaccine Government Disease International 52

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. billion in 2030. How do CROs solve the challenges of managing clinical trials?

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

The Pharma Data

MAY 3, 2021

Chronic disease care and management. “ Lilly is committed to helping address systemic inequities in health, including for those with non-communicable diseases such as diabetes, that too often have devastating effects on the lives of historically marginalized people,” said David A. www.lilly.com ?and? www.lilly.com/news.?I-LLY.

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

The Pharma Data

SEPTEMBER 16, 2020

SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%. Novartis is taking bold steps to increase patient reach in LMICs with its strategic innovative therapies by at least 200% by 2025.

Regulations 52

Regulations Therapies Government Disease 52

NIH Director's Blog: Drug Development

MAY 15, 2018

Credit: National Institute of Allergy and Infectious Diseases, NIH As a volunteer physician in a small hospital in Nigeria 30 years ago, I was bitten by lots of mosquitoes and soon came down with headache, chills, fever, and muscle aches. In 2016 alone, an estimated 216 million people were treated for the disease.

Drug Development 52

Drug Development Drugs Disease Vaccine 52

Drug Discovery World

MARCH 14, 2023

DDW’s Diana Spencer reviews some of the advances in drug discovery for diseases of the brain in the last month. As for haemorrhagic stroke, GlobalData forecasts suggest that the incidence rates in the US were 0.02% in 2022 and are predicted to rise to 0.03% by 2030. as of 2022, and that number is expected to slowly increase to 0.3%

Science 130

Science Disease RNA Clinical Trials 130